# A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Immunogenicity of HuL001

> **NCT04540770** · PHASE1 · COMPLETED · sponsor: **HuniLife Biotechnology, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** HuL001

## Key facts

- **NCT ID:** NCT04540770
- **Lead sponsor:** HuniLife Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-31
- **Primary completion:** 2022-03-04
- **Final completion:** 2024-01-19
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04540770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04540770, "A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Immunogenicity of HuL001". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04540770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*